Translating Molecular Biology Discoveries to Develop Targeted Cancer Interception in Barrett's Esophagus

Esophageal adenocarcinoma (EAC) is a rapidly increasing lethal tumor. It commonly arises from a metaplastic segment known as Barrett's esophagus (BE), which delineates the at-risk population. Ample research has elucidated the pathogenesis of BE and its progression from metaplasia to invasive ca...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2023-07, Vol.24 (14), p.11318
Main Authors: Samaddar, Sohini, Buckles, Daniel, Saha, Souvik, Zhang, Qiuyang, Bansal, Ajay
Format: Article
Language:English
Subjects:
Acids
Anti-inflammatory agents
Aspirin
Barrett’s esophagus
Bile
Cancer
Cell growth
chemoprevention
Development and progression
Diabetes therapy
esophageal adenocarcinoma
Esophageal cancer
Esophagus
Gastroesophageal reflux
Insulin resistance
Kinases
Lymphocytes
Metabolism
Molecular biology
Obesity
Prevention
Review
Sulindac
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Esophageal adenocarcinoma (EAC) is a rapidly increasing lethal tumor. It commonly arises from a metaplastic segment known as Barrett's esophagus (BE), which delineates the at-risk population. Ample research has elucidated the pathogenesis of BE and its progression from metaplasia to invasive carcinoma; and multiple molecular pathways have been implicated in this process, presenting several points of cancer interception. Here, we explore the mechanisms of action of various agents, including proton pump inhibitors, non-steroidal anti-inflammatory drugs, metformin, and statins, and explain their roles in cancer interception. Data from the recent AspECT trial are discussed to determine how viable a multipronged approach to cancer chemoprevention would be. Further, novel concepts, such as the repurposing of chemotherapeutic drugs like dasatinib and the prevention of post-ablation BE recurrence using itraconazole, are discussed.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms241411318